Meeting Trial Participants Where They Are
The COVID-19 pandemic significantly dislocated the operational model of traditional clinical trials as travel restrictions…
Anaeze C. Offodile II February 23, 2023
5 Results
Imagining Governance for Emerging Technologies
The authors examine a new methodology from the National Academy of Medicine that could inform social, ethical and legal governance frameworks for a range of cutting-edge technologies. Read more at Issues in Science and Technology.
Anaeze C. Offodile II July 23, 2022
Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?
The connection between Texas H.B. 810, which allows clinics to provide investigational stem cell treatments to certain patients, and a deregulation movement to increase patient access to unproven stem cell treatments is described in this report.
Kirstin R.W. Matthews, Bhavana Kunisetty, Keri Sprung October 25, 2018
A Need for Renewed and Cohesive U.S. Policy on Cord Blood Banking
While the Food and Drug Administration currently regulates storage and use of cord blood (CB) in the United States, other state and federal guidelines on CB education, awareness and ethical considerations remain variable, and no mandatory international guidelines exist. To help organize and coordinate efforts across the United States and other nations, policymakers should implement regulations for high quality standards for both private and public CB banks.
Monica M. Matsumoto, Kirstin R.W. Matthews August 4, 2015
Cancer Drugs in the United States: Justum Pretium — The Just Price
Allowing the producer-dominated market to set drug prices has spiraled the cost of cancer drugs out of control. Drug pricing can be reduced while preserving the profit-making incentive, by linking price to a true measure of quality: preservation and meaningful prolongation of life.
Hagop M. Kantarjian May 6, 2013